charg
neutral
steric
block
oligonucleotid
analogu
peptid
nucleic
acid
pna
phosphorodiamid
morpholino
oligom
pmo
promis
biolog
pharmacolog
properti
antisens
applic
exampl
mrna
splice
redirect
howev
cellular
uptak
free
oligom
poor
util
conjug
pna
pmo
cell
penetr
peptid
cpp
tat
penetratin
limit
endosom
sequestr
two
new
famili
argininerich
cpp
name
rahxr
ahxb
r
pen
allow
effici
nuclear
deliveri
splice
correct
pna
pmo
micromolar
concentr
absenc
endosomolyt
agent
vivo
efficaci
rahxr
ahxb
pmo
conjug
demonstr
mous
model
duchenn
muscular
dystrophi
variou
viral
infect
concept
synthet
oligonucleotid
potenti
therapeut
agent
first
demonstr
experiment
oligodeoxyribonucleotid
target
rou
sarcoma
viru
rna
translat
initi
site
use
form
rnadna
duplex
steric
block
rna
result
inhibit
gene
express
consequ
viral
replic
later
found
second
inhibitori
mechan
oper
cell
recognit
rna
dna
duplex
cellular
enzym
rnase
h
result
subsequ
rna
cleavag
henc
prevent
gene
express
second
mechan
action
becam
one
primarili
pursu
known
gener
antisens
led
industri
develop
therapeut
dnabas
analogu
control
gene
express
sadli
far
littl
clinic
success
origin
concept
inhibit
protein
translat
steric
block
continu
studi
recent
year
substrat
rnase
h
duplex
rna
begun
develop
therapeut
agent
addit
inhibit
mrna
translat
initi
also
design
steric
inhibit
critic
import
target
rna
process
exampl
nuclear
splice
seri
event
involv
numer
rnaprotein
interact
small
rna
involv
gene
control
target
vitro
vivo
endogen
microrna
effect
target
region
steric
block
inhibit
translat
gener
limit
start
codon
region
mrna
one
import
advantag
steric
block
approach
modul
gene
express
greater
specif
thu
potenti
lower
offtarget
effect
compar
convent
antisens
sinc
bind
partial
match
inappropri
rna
sequenc
unlik
biolog
consequ
second
advantag
abil
use
consider
wider
rang
synthet
analogu
possibl
convent
antisens
sinc
requir
molecular
recognit
cellular
rnase
h
instead
key
initi
necess
suitabl
steric
block
tight
bind
rna
target
well
good
resist
nucleas
degrad
greater
flexibl
manipul
chemistri
make
easier
also
focu
essenti
requir
therapeut
develop
good
deliveri
cell
tissu
low
toxic
pharmacolog
paramet
first
type
steric
block
becom
wide
establish
consist
fulli
ome
nucleosid
also
often
contain
phosphorothio
ps
linkag
ps
linkag
improv
cellular
uptak
metabol
stabil
pharmacolog
also
give
rise
reduc
rna
bind
sever
type
neg
charg
phosphatecontain
analogu
better
bind
rna
higher
resist
nucleas
degrad
exampl
moe
without
ps
linkag
np
bound
rna
target
analogu
type
adopt
alik
conform
similar
oligoribonucleotid
lock
nucleic
acid
lna
also
adopt
alik
conform
bind
tightli
rna
exampl
lna
on
use
vivo
tumour
growth
inhibit
lna
gener
use
combin
anoth
nucleotid
deriv
exampl
ome
residu
obtain
optim
balanc
bind
specif
characterist
altern
lnadna
contain
ps
linkag
found
give
effici
splice
switch
mice
luciferas
report
assay
use
show
omelna
mixmer
bound
strongli
transactiv
respons
element
tar
viral
rna
block
tatdepend
transactiv
hela
cell
howev
two
type
uncharg
analogu
peptid
nucleic
acid
pna
fig
phosphorodiamid
morpholino
oligom
pmo
also
known
morpholino
fig
come
domin
steric
block
applic
recent
although
depart
significantli
sugarphosph
backbon
found
regular
dna
oligom
type
retain
strong
sequencespecif
rna
bind
characterist
exampl
pna
target
luciferas
mrna
shown
inhibit
translat
protein
synthesi
pmo
also
found
remark
steric
block
on
inhibit
translat
alter
premrna
block
mirna
activ
demonstr
embryo
cell
anim
pmo
taken
preclin
studi
treatment
cardiovascular
diseas
viral
diseas
genet
disord
duchenn
muscular
dystrophi
dmd
see
section
despit
charg
neutral
pna
pmo
enter
cell
cultur
readili
neg
charg
exampl
mani
method
pna
deliveri
devis
electropor
microinject
transfect
complex
dna
lipofect
acridin
polyheteroarom
function
pna
photochemicallyinduc
deliveri
cell
transfect
effici
highli
variabl
sensit
small
variat
condit
type
transfect
method
use
best
achiev
ic
valu
usual
around
nm
model
splice
redirect
system
rel
high
molar
level
oligom
requir
obtain
signific
steric
block
action
compar
rnase
hdepend
mechan
action
short
interf
rna
sirna
probabl
due
need
deliv
least
stoichiometr
amount
rna
target
right
cell
compart
obtain
desir
biolog
effect
one
idea
enhanc
cell
deliveri
first
propos
year
ago
coval
conjug
cation
peptid
later
conjug
antisens
peptid
deriv
helix
antennapaedia
homeodomain
protein
drosophila
melanogast
residu
penetratin
shown
biolog
activ
neuron
cell
attribut
cell
penetr
properti
peptid
anoth
cell
penetr
peptid
cpp
discov
basic
region
tat
protein
residu
mani
cpp
also
known
protein
transduct
domain
remark
properti
cell
penetr
either
conjug
rang
type
biomolecul
peptid
protein
liposom
nanoparticl
characteris
review
howev
exampl
strong
deliveri
biolog
activ
neg
charg
sirna
cargo
cell
coval
attach
cpp
publish
review
mani
case
conjug
peptid
allow
suffici
cargo
deliveri
endocytot
pathway
cell
compart
necessari
biolog
activ
contrast
cpp
conjug
shown
signific
promis
toward
improv
cell
deliveri
charg
neutral
pna
pmo
pnapeptid
earli
exampl
block
express
galanin
receptor
mrna
human
bow
cell
pna
disulfidecoupl
cpp
penetratin
transportan
hybrid
section
neuropeptid
galanin
wasp
venom
peptid
mastoparan
constitut
step
toward
modif
pain
transmiss
remark
potent
inhibit
nm
ec
model
claim
shorter
pna
target
differ
region
mrna
conjug
truncat
transportan
version
except
sinc
cellular
inhibit
protein
translat
pna
achiev
rang
exampl
pna
disulfidelink
penetratin
abl
inhibit
telomeras
activ
melanoma
cell
ic
differ
model
system
amphipath
peptid
map
disulfideconjug
pna
complementari
nociceptinorphanin
fq
receptor
mrna
shown
impart
improv
cell
uptak
steric
block
biolog
effect
cho
cell
neonat
rat
cardiomyocyt
rang
link
aakk
peptid
pna
complementari
human
caveolin
mrna
inhibit
express
hela
cell
ic
primari
endotheli
cell
concentr
n
cpppmo
conjug
use
success
cell
cultur
anim
model
inhibit
replic
sever
virus
harm
human
includ
exampl
coxsackieviru
sar
coronaviru
influenza
dengu
west
nile
ebola
virus
see
section
addit
applic
cpppna
cpppmo
translat
block
mention
pmo
pna
deliv
cpp
use
alter
premrna
splice
pna
ad
ly
residu
k
complementari
splice
site
within
enhanc
green
fluoresc
protein
egfp
report
gene
contain
aberr
human
intron
enough
result
splice
correct
upregul
egfp
hela
cell
cultur
assay
transgen
mice
k
show
activ
sever
tissu
heart
kidney
lung
liver
muscl
small
intestin
deliv
intraperiton
mgkg
day
splice
correct
observ
cpppmo
conjug
also
use
effect
alter
premrna
splice
dmd
model
dmd
usual
caus
nonsens
frameshift
exon
mutat
dystrophin
gene
result
absenc
function
protein
rahxr
ahxbpmo
r
arginin
ahx
acid
b
betaalanin
conjug
use
sever
model
promot
skip
mutat
exon
produc
intern
shorten
function
dystrophin
protein
rahxr
ahxbpmo
conjug
much
effect
caus
desir
exonskip
primari
muscl
cell
isol
golden
retriev
muscular
dystrophi
dog
correspond
nonconjug
pmo
ome
nm
extracellular
concentr
conjug
caus
complet
exonskip
muscl
cell
ten
day
singl
treatment
conjugatetr
cell
continu
show
abund
exonskip
rna
product
anoth
rahxr
pmo
conjug
caus
desir
exonskip
mdx
mous
muscl
explant
sever
muscl
intact
mdx
mice
see
section
rahxr
ahxbpmo
alter
premrna
splice
primari
murin
splenic
tcell
pmo
target
splice
acceptor
site
premrna
cell
surfac
signal
protein
nuclear
transcript
factor
treatment
tcell
conjug
result
mark
reduct
protein
express
h
remov
conjug
detect
splicealt
gene
product
h
remov
conjug
sever
studi
use
model
cell
cultur
system
involv
splice
redirect
murin
premrna
caus
downregul
activ
pna
complementari
splice
site
ly
residu
nterminu
significantli
activ
cell
cultur
similar
pna
ly
residu
still
concentr
need
strong
downregul
target
bcl
cell
primari
murin
macrophag
varieti
stabli
link
pna
conjug
various
space
oligoli
peptid
show
small
enhanc
splice
redirect
activ
case
compar
ly
seri
cation
peptid
base
ly
arg
amphipath
charact
show
even
stronger
splice
redirect
activ
concentr
without
toxic
vivo
efficaci
construct
yet
report
particularli
use
splice
redirect
model
system
develop
kole
colleagu
base
use
stabli
integr
plasmid
contain
gene
code
firefli
luciferas
interrupt
aberr
intron
infram
stop
codon
upregul
luciferas
result
psome
oligonucleotid
complementari
aberr
splice
site
introduc
hela
cell
redirect
splice
use
sensit
splice
redirect
model
allow
optim
cpp
conjug
technolog
deliveri
pna
pmo
nuclear
compart
sinc
experi
conjug
cpp
neg
charg
result
level
deliveri
cell
suffici
biolog
activ
concentr
pnaand
pmopeptid
conjug
much
success
gener
review
describ
method
synthesi
peptideon
conjug
publish
peptid
pna
synthes
similar
sequenti
coupl
reaction
monom
unit
solid
support
form
amid
bond
strategi
manual
autom
pna
synthesi
fmocbhoc
tertbutyloxycarbonylcarbobenzyloxi
boc
cbz
rout
well
establish
thu
peptidepna
conjug
may
assembl
continu
synthesi
activ
amino
acid
activ
pna
monom
ad
coupl
reaction
gener
restrict
combin
amino
acid
pna
residu
may
ad
order
common
includ
least
one
ly
residu
end
pna
synthesi
aid
water
solubl
fmocbhoc
chemistri
often
prefer
pna
assembl
report
protocol
pna
pnapeptid
synthes
use
robot
apex
synthes
short
polyeth
spacer
aeea
acid
also
known
olink
often
ad
peptid
pna
moieti
continu
synthesi
fig
altern
fragment
conjug
presynthes
peptid
pna
compon
solut
usual
conveni
structureact
sar
studi
overal
yield
puriti
final
conjug
gener
higher
fragment
synthes
separ
solidphas
contain
specif
function
one
end
fragment
purifi
prior
conjug
step
usual
excess
one
compon
ad
drive
conjug
reaction
complet
product
conjug
purifi
hplc
character
mass
spectrometri
gener
rule
yet
emerg
optim
linkag
type
sinc
factor
affect
biolog
activ
often
complex
exampl
studi
use
labil
disulfid
linkag
result
higher
biolog
activ
contrast
stabl
thioether
linkag
disulfid
linkag
gave
equal
good
result
splice
redirect
system
sever
type
stabl
linkag
report
exampl
thiolmaleimid
linkag
requir
addit
cy
residu
cpp
prepar
nmaleimid
deriv
pna
may
obtain
reaction
termin
primari
amino
group
heterobifunct
crosslink
succinimidyl
nmaleimidomethyl
fig
thioether
linkag
may
form
bromoacetyl
cyscontain
peptid
adapt
reaction
conjug
cpp
contain
cy
residu
cterminu
ntermin
bromoacetyl
pna
fig
estercontain
conjug
synthes
pna
bear
glycyl
hydroxymethyl
benzoic
acid
residu
nterminu
linkag
design
labil
esteras
within
cell
fig
howev
popular
labil
linkag
disulfid
bond
peptid
cpp
fig
propos
cleavabl
within
reduc
environ
cell
first
use
studi
transportanpna
penetratinpna
conjug
cpp
pna
function
cy
residu
disulfid
bond
form
cy
thiol
group
one
thiol
activ
reaction
either
pyridylsulfenyl
group
use
disulfid
linkag
predominantli
studi
hiv
tatdepend
transactiv
inhibit
splice
redirect
disulfid
linkag
conveni
vitro
cell
studi
even
though
may
less
suitabl
vivo
use
pmo
synthes
describ
previous
cpp
may
synthes
standard
fmoc
chemistri
conjug
cpp
pmo
thioether
maleimid
disulfid
amid
linker
describ
previous
structur
conjug
shown
fig
effect
linker
type
activ
stabil
cpppmo
conjug
determin
nuclear
antisens
activ
cpppmo
three
linkag
type
similar
moulton
h
unpublish
result
synthet
amid
linkag
two
advantag
disulfid
thioether
linkag
first
pmo
easili
conjug
cpp
via
amin
either
end
oligom
second
format
amid
bond
requir
onestep
synthet
purif
scheme
compar
twostep
strategi
linkag
therefor
amid
linkag
lead
overal
greater
yield
cpppmo
addit
amid
bond
appear
stabl
vivo
sinc
unhind
disulfidelink
cpppmo
found
unstabl
human
serum
although
cpp
conjug
either
end
pmo
posit
cpp
affect
activ
attach
pmo
pmo
cpp
conjug
function
activ
cpp
attach
ad
bulki
fluorochrom
carboxyfluorescein
pmo
decreas
activ
cpppmo
unpublish
data
point
section
varianc
numer
report
success
peptid
payload
success
deliveri
antisens
cpp
often
document
nielsen
colleagu
investig
cellular
uptak
sever
pnacpp
construct
live
cell
avoid
artefact
redistribut
caus
cell
fixat
pnatat
pnapenetratin
construct
taken
energydepend
mechan
essenti
accumul
endocytot
vesicl
nuclei
keep
data
although
encourag
first
sight
data
could
predict
whether
biolog
effect
would
achiev
exampl
even
though
fusion
construct
cre
recombinas
tat
cpp
seem
remain
local
endocytot
vesicl
gave
rise
signific
biolog
activ
mention
section
mani
group
field
deliveri
reli
splice
redirect
model
kole
assess
nuclear
deliveri
steric
block
model
use
virtu
highli
sensit
sequencespecif
provid
posit
readout
low
background
level
give
rise
linear
respons
larg
rang
concentr
luciferas
express
howev
highli
sensit
cell
densiti
variabl
point
bendifallah
et
al
rtpcr
evalu
splice
correct
easi
implement
give
estim
proport
misversu
correctlyspl
luciferas
mrna
may
therefor
prefer
luciferas
assay
tatand
argpmo
construct
gave
rise
sequencespecif
correct
missplic
luciferas
premrna
howev
high
concentr
higher
correct
steric
block
requir
achiev
luciferas
express
point
comparison
ome
moe
rapidli
accumul
nuclei
led
splice
correct
dose
low
nm
transfect
cation
lipid
likewis
tat
argand
penetratinpna
construct
poorli
effici
splice
redirect
assay
low
concentr
seri
public
report
success
splice
correct
pna
append
short
oligolysin
chain
review
section
intriguingli
splice
correct
claim
energyindepend
varianc
recent
data
mechan
cellular
uptak
basic
amino
acidrich
cppconjug
hand
ly
pna
conjug
effici
taken
cell
monitor
fac
analysi
fluoresc
microscopi
biolog
activ
remain
rather
low
keep
previou
data
tator
argrich
steric
block
conjug
interestingli
cellular
uptak
clearli
energydepend
low
concentr
becam
temperatureindepend
high
concentr
parallel
membran
destabil
monitor
propidium
iodid
uptak
endocytosi
may
thu
predomin
mechan
uptak
low
concentr
direct
transloc
link
cppinduc
membran
destabil
could
take
place
higher
concentr
cppinduc
membran
permeabil
may
rather
depend
peptid
cell
type
experiment
condit
provid
possibl
explan
ongo
controversi
concern
cpp
mechan
cell
uptak
sequestr
intern
materi
endocytot
vesicl
could
also
explain
observ
low
biolog
activ
variou
cpp
conjug
inde
treatment
endosomolyt
agent
chloroquin
high
sucros
gave
rise
larg
increas
splice
correct
activ
even
ad
cpppna
intern
similarli
hela
cell
assay
contain
integr
luciferas
report
plasmid
cation
lipidtransfect
omelna
on
target
tar
element
abl
dosedepend
inhibit
tatdepend
transactiv
howev
cpp
conjug
tat
pen
pna
target
tar
incub
hela
cell
unabl
inhibit
transactiv
unless
chloroquin
ad
even
cpppna
show
inhibit
requir
h
incub
show
activ
endosom
sequestr
appear
explan
result
altern
endosom
disrupt
strategi
evalu
use
splice
correct
assay
addit
ca
high
concentr
mm
cultur
medium
strongli
increas
splice
correct
tator
arg
pna
construct
evid
partial
redistribut
endocytot
vesicl
cytoplasm
obtain
nuclear
stain
observ
likewis
chloroquin
treatment
improv
function
activ
cpppna
cpppmo
conjug
unabl
detect
nuclear
accumul
conjug
oligom
abe
et
al
unpublish
observ
event
none
endosomedisrupt
strategi
like
feasibl
vivo
therefor
sever
group
explor
altern
strategi
cotreat
endosomedisrupt
peptid
studi
extens
improv
plasmid
dna
transfect
nonvir
deliveri
vector
synthet
mostli
amphipath
natur
mostli
viral
endosomedisrupt
peptid
describ
popular
ntermin
peptid
influenza
viru
protein
refer
therein
fusion
construct
slightli
increas
splice
correct
tat
penor
transportanpna
conjug
likewis
addit
sever
natur
synthet
membran
destabil
peptid
tatpna
modest
effect
splice
correct
noncytotox
dose
photochem
intern
pci
capit
product
reactiv
oxygen
speci
damag
endosom
upon
irradi
thu
facilit
escap
endosomeentrap
drug
pci
exploit
success
increas
uptak
variou
biomolecul
low
molecular
weight
drug
plasmid
dna
hovig
document
pciinduc
gene
silenc
sever
pnacpp
construct
togeth
reloc
pnapeptid
endosom
nuclei
shiraishi
et
al
provid
similar
data
pnacpp
construct
aim
splice
correct
pci
thu
repres
interest
strategi
overcom
endosom
entrap
cppon
sinc
amen
vivo
develop
structureact
studi
cpp
deriv
protein
tat
penetratin
synthet
cpp
emphas
crucial
role
play
basic
amino
acid
particularli
guanidinium
sidechain
arginin
basic
amino
acid
respons
bind
cell
surfac
heparan
sulfat
proteoglycan
hspg
electrostat
interact
subsequ
cell
intern
rxr
famili
synthet
cpp
first
propos
j
rothbard
pa
wender
colleagu
assumpt
arg
side
chain
oligo
arg
peptid
would
point
direct
would
therefor
avail
hspg
membran
lipid
polar
head
bind
accordingli
design
synthes
larg
collect
rxr
n
r
rx
n
r
rxx
n
r
rxxx
n
r
transport
peptid
x
repres
variou
natur
nonnatur
amino
acid
peptid
conjug
fluorescein
assay
cellular
uptak
jurkat
cell
line
studi
emphas
crucial
role
arg
side
chain
space
cellular
uptak
effici
peptid
rahxr
r
ahx
repres
aminohexano
acid
spacer
strategi
interspers
arg
residu
nonnatur
uncharg
amino
acid
also
appear
interest
decreas
number
natur
peptid
bond
thu
provid
increas
metabol
stabil
decreas
posit
charg
densiti
often
respons
cytotox
howev
studi
biolog
respons
report
although
synthesi
conjug
cyclosporin
acyclovir
describ
rahxr
chosen
therefor
lead
peptid
stabli
conjug
pmo
oligom
via
linker
varianc
tatpmo
arg
pmo
conjug
rahxr
ahxbpmo
lead
dosedepend
specif
increas
luciferas
express
absenc
endosomolyt
agent
importantli
signific
increas
could
alreadi
observ
submicromolar
concentr
mention
measur
luciferas
express
allow
function
comparison
variou
cpp
construct
allow
quantif
splice
redirect
therefor
made
use
rtpcr
easili
discrimin
correctli
aberrantlyspl
luciferas
transcript
confirm
highli
signific
splice
correct
could
achiev
concentr
rahxr
ahxbpmo
rahxr
also
stabli
conjug
splice
correct
pna
oligom
found
effect
concentr
rang
interestingli
vivo
applic
rahxr
construct
show
membran
permeabil
dose
ie
concentr
tat
ly
n
arg
n
construct
lead
signific
propidium
iodid
uptak
compar
mechan
cellular
intern
fluorochromelabel
rahxr
ahxbpmo
tatpmo
arg
n
pmo
search
mechanist
explan
differ
effici
surprisingli
rahxr
construct
taken
less
effici
tator
arg
n
one
varianc
data
report
rothbard
et
al
increas
activ
could
explain
nonendocytot
uptak
rout
studi
involv
energi
depriv
use
endocytosi
inhibitor
support
hypothesi
studi
need
clarifi
issu
along
line
fluoresc
microscopi
studi
live
cell
reveal
major
rahxr
ahxbpmo
distribut
dot
cytoplasm
spot
characterist
accumul
endocytot
vesicl
similar
conclus
reach
use
function
assay
splice
redirect
assess
energydepend
rahxr
ahxbpmo
conjug
fig
expect
rahxr
ahxbpmo
bind
cell
surfac
hspg
reveal
genet
biochem
tool
possibl
interest
rahxr
construct
bind
sepharoseimmobil
heparin
taken
model
heparan
sulfat
conjug
intern
energydepend
mechan
splice
correct
assay
use
assess
energydepend
atp
depriv
lane
low
temperatur
incub
lane
hela
pluc
cell
preincub
h
optimem
supplement
mm
sodium
azid
mm
optimem
cell
incub
pmo
conjug
indic
concentr
h
condit
cell
wash
incub
continu
h
dmem
total
rna
extract
amplifi
rtpcr
pcr
product
incorrectli
bp
band
correctli
bp
band
splice
luciferas
premrna
separ
agaros
gel
lane
control
absenc
rahxr
ahxbpmo
conjug
cell
incub
treat
rahxr
ahxbpmo
respect
cell
incub
presenc
mm
sodium
azid
mm
treat
rahxr
ahxbpmo
respect
cell
incub
treat
rahxr
ahxbpmo
respect
significantli
lower
affin
tator
arg
n
construct
could
lead
improv
effici
one
postul
hspgbound
ligand
need
dissoci
cellular
intern
order
escap
endocytot
vesicl
sar
studi
seri
rxr
ahxbpmo
construct
x
vari
term
length
affin
heparin
hydrophob
conduct
abe
et
al
prepar
studi
demonstr
increas
hydrophob
affin
heparin
improv
cellular
uptak
detriment
effici
splice
correct
briefli
mention
rahxr
lower
number
adjac
natur
amino
acid
cpp
factor
could
increas
metabol
stabil
consequ
biolog
effici
although
serum
stabil
inde
increas
analysi
intracellular
cleavag
product
support
hypothesi
furthermor
introduct
darg
residu
give
drahxr
rpmo
purpos
increas
resist
proteolysi
lead
increas
splice
correct
effici
thu
indic
metabol
stabil
limit
function
efficaci
abe
et
al
prepar
altogeth
definit
explan
superior
activ
rahxr
argrich
cpp
provid
present
sar
endosom
escap
studi
hope
shed
light
mysteri
contribut
design
activ
steric
block
deliveri
vector
note
recent
result
use
fluoresc
microscopi
splice
correct
assay
show
larg
percentag
rahxr
ahxbpmo
enter
cell
appear
local
endocytot
vesicl
even
dose
produc
nearli
complet
splice
correct
result
incompat
sinc
steric
block
conjug
appli
concentr
missplic
premrna
target
express
far
lower
molar
concentr
second
class
argrich
cpp
studi
known
r
pen
base
well
known
penetratin
peptid
six
arg
residu
ad
nterminu
first
synthes
conjug
omelna
oligonucleotid
r
pen
disulfideconjug
pna
complementari
transactiv
respons
element
tar
found
enter
hela
cell
nuclei
inhibit
tatdepend
transactiv
luciferas
plasmid
assay
system
submicromolar
concentr
dosedepend
pna
sequencedepend
activ
could
achiev
readili
r
penpna
incub
hela
cell
presenc
endosomolyt
reagent
chloroquin
suggest
endocytot
mode
cell
uptak
similarli
rahxr
pna
pmo
conjug
r
penpna
conjug
target
splice
acceptor
site
show
potent
sequencespecif
correct
hela
cell
assay
low
concentr
absenc
endosomolyt
agent
mechan
cell
intern
r
yet
thoroughli
investig
clearli
energydepend
like
involv
endocytosi
abe
et
al
unpublish
result
employ
splice
redirect
assay
use
rtpcr
measur
level
aberrantli
correctlyspl
rna
transcript
r
pen
activ
cpppna
conjug
investig
far
group
fig
yet
clear
r
pen
effici
cpp
penetratin
exampl
essenti
differ
document
use
mutant
r
pen
peptid
trp
residu
known
essenti
pen
peptid
penetr
membran
replac
leu
residu
r
pen
w
l
mutant
even
activ
wildtyp
r
pen
version
fig
suggest
mechan
cell
entri
releas
cytosol
nucleu
must
differ
significantli
r
penpna
conjug
pen
peptid
import
append
oligoarg
tail
affirm
vari
number
arg
residu
neither
shorter
longer
tail
effici
origin
r
pen
peptid
sar
studi
underway
aim
understand
better
role
variou
domain
r
pen
peptid
enhanc
conjug
activ
serum
stabil
decreas
cytotox
oftendeb
issu
natur
linker
cpp
deliveri
vector
transport
payload
mention
section
role
deliveri
vector
obvious
transport
cargo
intracellular
site
intracellular
dissoci
two
entiti
would
intuit
prefer
sinc
would
predict
avoid
steric
hindranc
potenti
complic
howev
situat
complex
steric
block
analogu
sinc
bound
highli
charg
deliveri
peptid
increas
affin
target
rna
sequenc
favour
invas
secondari
structur
thu
lead
enhanc
activ
thu
compar
splice
correct
effici
specif
pna
sequenc
conjug
r
pen
stabl
thioether
reduc
disulfid
linker
disulfidelink
materi
slightli
effici
stabli
link
one
fig
data
gather
far
stabli
link
rahxr
r
pen
conjug
indic
append
cpp
prevent
target
recognit
alter
oligom
sequenc
specif
altern
similar
activ
stablyand
disulfidelink
materi
could
due
equal
rate
intracellular
degrad
peptid
deliveri
vector
compound
vivo
data
splice
modul
bioavail
toxic
dmd
xlink
recess
diseas
caus
muscl
degener
decreas
span
qualiti
life
affect
human
mous
model
muscular
dystrophi
mdx
use
studi
effect
free
pmo
cpppmo
conjug
mdx
mice
carri
nonsens
mutat
exon
excis
exon
mdx
mous
cell
restor
mostlyfunct
dystrophin
express
unconjug
pmo
target
donor
site
exon
partial
restor
dystrophin
function
skelet
muscl
mdx
mice
mgkgdose
intraven
mgkgdose
intraperiton
consecut
weekli
dose
pmo
conjug
rahxr
ahxb
cpp
produc
high
efficaci
administ
intraperiton
mgkg
dose
week
week
dystrophin
level
diaphragm
muscl
mdx
mice
detect
two
week
singl
intraperiton
inject
rahxr
ahxbpmo
similar
level
normal
mice
four
dose
conjug
mgkgdose
administ
week
four
week
neonat
mice
result
normal
level
dystrophin
diaphragm
mice
week
post
fourth
inject
dystrophin
still
detect
diaphragm
conjug
effect
lower
tibiali
anterior
gluteu
maximu
tricep
brachiali
weaker
still
colon
stomach
absent
heart
western
blot
detect
normal
level
dystrophin
diaphragm
six
week
lower
level
tibiali
gluteu
dystrophin
detect
cardiac
muscl
anim
one
day
four
week
one
year
age
treat
test
effect
age
whilst
splicemodifi
dystrophin
express
increas
age
treat
muscl
architectur
improv
mice
treat
younger
age
normal
patholog
central
nucleat
observ
section
taken
mice
treat
rahxr
ahxbpmo
studi
reveal
treatment
dmd
mice
young
age
benefici
older
age
tissu
distribut
pharmacokinet
pmo
correspond
rahxr
ahxb
conjug
administr
intraven
determin
rat
conjug
pmo
rahxr
ahxb
peptid
increas
tissu
uptak
retent
cpp
conjug
increas
uptak
pmo
organ
assay
except
brain
greater
increas
seen
liver
spleen
lung
remark
similar
amount
pmo
still
detect
liver
day
last
dose
indic
conjug
pmo
long
retent
time
organ
interestingli
concentr
conjug
pmo
rat
spleen
assay
day
last
dose
twice
concentr
rat
spleen
assay
day
last
dose
result
suggest
efflux
conjug
pmo
tissu
vascular
space
slow
import
consider
therapeut
applic
conjug
pmo
rahxr
ahxb
improv
kinet
behaviour
pmo
demonstr
increas
volum
distribut
increas
estim
elimin
half
life
increas
area
plasma
concentr
versu
time
curv
stabil
cpppmo
conjug
vari
cpp
sequenc
amino
acid
composit
andor
linker
studi
cell
human
serum
stabil
peptid
moieti
serum
rank
order
dcpp
rahx
ahxb
n
r
f
c
tat
stabil
peptid
moieti
within
cell
found
dcpp
n
rb
b
n
rahx
b
rahxr
ahxb
r
f
c
tat
stabil
linker
serum
cell
found
amid
maleimid
n
disulfid
stabil
rahxr
ahxbpmo
determin
rat
serum
organ
lysat
cpp
portion
conjug
exhibit
timeand
tissuedepend
degrad
biolog
stabil
rank
order
liver
nheart
kidney
n
plasma
h
cpp
portion
cpppmo
partial
degrad
plasma
appar
degrad
tissu
pmo
portion
conjug
complet
stabl
cell
serum
plasma
tissu
toxic
rahxr
ahxbpmo
caus
rahxr
ahxb
pmo
portion
conjug
essenti
nontox
degre
toxic
depend
dose
dose
frequenc
rout
administr
mice
toler
rahxr
ahxbpmo
well
repeat
dose
mgkg
four
daili
ip
inject
mice
mgkg
rahxr
ahxbpmo
conjug
produc
observ
toxic
chang
mice
behaviour
weight
serum
chemistri
observ
mdx
mice
inject
intraperiton
conjug
mgkg
week
four
week
histopatholog
abnorm
detect
heart
liver
kidney
spleen
pancrea
two
iv
dose
rahxr
ahxbpmo
conjug
administ
h
apart
mgkg
howev
higher
dose
dose
frequenc
anim
experienc
weight
loss
mice
lost
weight
five
daili
dose
ip
mgkg
rahxr
ahxbpmo
conjug
despit
maintain
normal
organ
weight
appear
fibrosi
found
liver
treat
anim
mice
regain
normal
weight
treatment
stop
five
daili
intraven
inject
rahxr
ahxbpmo
rat
mgkg
caus
detect
toxic
measur
behaviour
appear
eatingdrink
habit
bodi
weight
serum
chemistri
rat
treat
singl
mgkg
dose
appear
letharg
immedi
inject
proceed
lose
weight
accompani
elev
serum
bun
creatinin
indic
kidney
function
like
affect
ld
rahxr
ahxbpmo
rat
around
mgkg
abil
cpp
deliv
steric
block
pna
pmo
treatment
viral
genet
diseas
demonstr
number
public
cell
cultur
vivo
studi
carri
far
vivo
cpppna
conjug
exampl
pnali
show
activ
sever
tissu
heart
kidney
lung
liver
muscl
small
intestin
deliv
ip
mgkg
day
transgen
mice
egfp
splice
correct
model
without
show
acut
toxic
pna
complementari
enhanc
intron
sequenc
stabli
link
nl
peptid
inhibit
cmyc
oncogen
express
burkitt
lymphoma
bl
cell
show
littl
toxic
human
tumour
scid
mice
model
inocul
subcutan
nlspna
show
inhibit
bl
cellinduc
tumour
growth
scid
mice
pna
conjug
k
show
broad
tissu
distribut
mice
iv
inject
rel
slow
excret
level
wherea
two
lysargrich
amphipath
dpeptid
stabli
conjug
pna
distribut
substanti
differ
mice
contrast
cpppmo
conjug
taken
numer
preclin
studi
exampl
cpp
shown
power
vector
deliv
pmo
cytosol
cell
number
report
cpppmo
inhibit
viru
replic
cell
cultur
mous
model
coxsackieviru
picornaviru
signific
caus
myocard
especi
children
adolesc
rahxr
ahxbpmo
target
intern
ribosom
entri
site
ire
utr
coxsackieviru
viral
genom
reduc
viral
titer
log
viru
infect
cell
cultur
two
mgkg
dose
irestarget
compound
administ
intraven
h
day
infect
viru
reduc
heart
tissu
damag
viral
titer
measur
one
week
postinfect
recent
emerg
sever
acut
respiratori
syndrom
sar
coronaviru
rais
threat
worldwid
pandem
experi
cultur
cell
show
antisens
r
f
cpmo
dramat
reduc
virusinduc
cytopath
effect
viral
titer
cell
cell
spread
viru
recent
mous
model
varieti
murin
coronavirus
rahxr
ahxbpmo
administr
intraperiton
reduc
liver
damag
viral
titer
reflect
improv
surviv
observ
influenza
viru
fluav
caus
consider
impact
human
health
everi
year
also
pose
pandem
threat
panel
cppconjug
pmo
target
variou
locat
fluav
gene
segment
involv
viral
rna
synthesi
show
npdirect
compound
found
markedli
inhibit
replic
viral
strain
test
includ
effect
compound
target
sequenc
highli
conserv
across
fluav
strain
subtyp
dengu
viru
denv
caus
million
case
dengu
fever
yearli
requir
hospit
death
world
popul
current
expos
potenti
infect
steric
block
r
f
r
cpmo
specif
inhibit
denv
replic
cell
cultur
experi
similarli
rahxr
ahxbpmo
potent
reduc
viral
titer
anoth
flaviviru
west
nile
viru
wnv
cell
cultur
experi
improv
surviv
compar
control
wnv
mous
model
ebola
viru
caus
sever
hemorrhag
fever
fatal
rate
human
vivo
mous
model
preor
postinfect
treatment
r
f
cpmo
conjug
rescu
mice
otherwiseleth
ebola
viru
infect
expect
cpp
continu
use
research
tool
deliv
pmo
pna
studi
variou
biolog
process
includ
splice
correct
lead
potenti
therapeut
applic
treatment
dmd
howev
cpp
toxic
endosom
entrap
appear
limit
factor
potenti
system
deliveri
steric
block
on
human
futur
studi
natur
toxic
endosom
entrap
uptak
mechan
cppon
hope
instruct
design
next
gener
cpp
higher
therapeut
index
current
time
cppon
suitabl
diseas
amen
either
local
treatment
infrequ
system
dose
dmd
perhap
small
number
system
treatment
acut
viral
infect
initi
phase
ibii
clinic
trial
evalu
safeti
efficaci
cpppmo
conjug
exvivo
treatment
vein
tissu
coronari
arteri
bypass
graft
start
poland
ukrain
clinic
trial
evalu
rahxr
ahxbpmo
target
human
cmyc
design
prevent
inappropri
cell
prolifer
occur
graft
procedur
frequent
caus
eventu
failur
graft
vein
excis
vein
tissu
immers
solut
contain
min
implant
bypass
graft
wwwclinicaltrialsgov
hope
clinic
trial
cpppmo
becom
possibl
soon
commerci
develop
cpppna
well
